Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Candidiasis

Candidiasis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Candidiasis

8 trials tracked for Candidiasis: 4 in phase 3 or 4.

8Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 2 Phase 1 1 Other / NA 1
  1. Phase 4 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Completed
  2. Phase 4 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed
  3. Phase 3 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed
  4. Phase 3 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed
  5. Phase 2 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection Completed
  6. Phase 2 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed
Show 2 more trials
  1. Phase 1 Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine Completed
  2. N/A Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Probiotics and postbiotics demonstrate anti-Candida activity by inhibiting growth, biofilm formation, and virulence genes
Infectious Disease Meta-analysis
Probiotics and postbiotics demonstrate anti-Candida activity by inhibiting growth, biofilm formation, and virulence genes Probiotics and postbiotics show potential against Candida yeast infections
This systematic review evaluates the anti-Candida activity of probiotics and postbiotics. The authors found that these interventions consist…
New evidence suggests that specific probiotics and their byproducts may help block the growth and spread of Candida yeast infections.
Frontiers Sep 24, 2026
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals
Infectious Disease Meta-analysis
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals New data shows prevalence of fungal infections in HIV patients
This meta-analysis evaluated the prevalence of opportunistic fungal infections in a population of HIV-positive individuals in Ethiopia. The …
New data reveals how common dangerous fungal infections like candidiasis and meningitis are among people living with HIV in Ethiopia.
NEJM Aug 22, 2026
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro
Infectious Disease Sys. Review
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro Could common diabetes drugs help stop fungal infections from building tough protective shields?
This systematic review evaluated alpha-glucosidase inhibitors, particularly acarbose, as selective antifungal inhibitors against Candida alb…
A common diabetes drug called acarbose may help break down the tough shields that hide dangerous fungal infections from treatment.
Frontiers Apr 14, 2026